Amphastar Pharma: Gains on FDA nod for atropine sulfate injection

Amphastar Pharmaceuticals,

06/10/2020 12:34

** Shares of drugmaker  AMPH.O  rise ~7% to $21.51 in
premarket trade
    ** The U.S. Food and Drug Administration approves co's
abbreviated new drug application for atropine sulfate injection
 urn:newsml:reuters.com:*:nGNX4WBp1c
    ** Atropine sulfate injection is used as a preoperative
measure to reduce salivary and bronchial secretions 
    ** Net revenue for Amphastar's atropine sulfate injection
for the year ended Dec. 31, 2019 was $12.2 mln - Amphastar 
    ** Stock had risen 4.4% this year, as of last close 

 (Reporting by Sanjana Shivdas in Bengaluru)
 ((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))